The XVII International AIDS Conference (AIDS 2008) will be held in Mexico City, Mexico from 3-8 August 2008. AIDS 2008 will be the first time a country in Latin America has hosted the Conference, and IAVI will be there to participate in a series of events, as well as to report on the state of AIDS vaccine research and development.
READ MORE >
HIV/AIDS: The Search for a Vaccine
Originally aired as part of BBC World’s Kill or Cure? series, this four-minute documentary features AIDS specialists, researchers, and community workers discussing the impact of HIV/AIDS on their communities and their efforts to find a solution to the epidemic. WATCH THE VIDEO DOWNLOAD THE PODCAST
Why the world needs an AIDS vaccine
Despite the international community's best efforts, the HIV pandemic continues unabated. In 2006, more than
39 million people were living with HIV worldwide. Over four million people became newly infected with HIV and an
estimated 2.8 million lost their lives to AIDS. LEARN MORE >
What is a vaccine?
A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a
certain pathogen (any disease-causing organism, such as a virus, bacterium or parasite); the vaccine 'teaches' the
body how to defend itself against a pathogen by creating an immune response. LEARN MORE >
Dr. Thomas Hassell joins IAVI as vice president for vaccine development, bringing with him a wealth of skills and experience - from preclinical studies to licensure - directly relevant to the development of new vaccines.
On May 18, we honor the individuals who work tirelessly to help make an AIDS vaccine a reality, and reflect on the considerable advances the world has made in AIDS vaccine science.
In an opinion piece published in the Wall Street Journal, IAVI President and CEO Seth Berkley challenges the pessimism surrounding recent AIDS vaccine media coverage and states that there are sound scientific reasons to believe we can create a vaccine against AIDS.
New Markets Tax Credit Helps Finance IAVI AIDS Vaccine Development Lab Construction
The National Community Fund I, LLC and Greystone CDE, LLC have chosen IAVI’s new AIDS Vaccine Development Laboratory to be the recipient of a New Markets Tax Credit, a financing program designed to spur investment in businesses and create jobs in low-income communities.
New York:
